Israeli company, Cannassure Therapeutics, recently announced that they’ve hit a new company milestone in their research of various cannabinoids.
According to the press release, Cannassure successfully completed their medical cannabis analytical method development and validation, in compliance with the requirements set forth by the Israeli Medical Cannabis Authority (IMCA). The project was led by Dana Marom, VP QA, and conducted by the company’s R&D and QA teams, and a regulatory consulting team from GSAP.
Cannassure is located in Ashdod, Israel and their goal is to develop and provide high-quality medical cannabis products and cannabinoid-based medications. This company is a spin-off of Solbar Food Technologies, a leading manufacturer of food products in Israel for the last 60 years. They are in the process of launching a “holistic and integrated medical cannabis value chain operation to commercialize a wide range of effective, high standard and affordable medical cannabis products and pharmaceutical cannabinoid medicines.”
Their analysis studied seven different cannabinoids – the main ones, tetrahydrocannabinol (THC) and cannabidiol (CBD), plus tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabinol (CBN), cannabinochromene (CBC) and cannabigerol (CBG). They observed the cannabinoids in different mediums such as flowers, extracts, and tinctures to measure the quality, consistency, and stability of their medical products which utilize them. All of Cannassure’s products meet GMP and pharmaceutical industry regulatory requirements.
“Cannassure has the knowhow to conduct our own testing of cannabis and medical cannabis products in a fast and reliable manner, without the need of external suppliers. This is completely in line with the company’s strategy of establishing a holistic medical cannabis production facility. Our vertically integrated operation will include advanced agritech breeding, an indoor grow operation, a state-of-the-art extraction and processing facility, together with scientifically advanced R&D,” states Cannassure CEO Ran Amir.